Even at a 100% premium, Moderna would get facilities ready to go and probably cheaper than building a greenfield site.
They’d also be eliminating a potential competitor.
The bottleneck in Moderna’s production is fill and finish so I think they would still want more capacity than 100 million doses per year.
IDT hasn’t been written off yet. Still plenty of potential to develop its own mRNA vaccine with MIPS and others, and also contract fill and finish for Novavax or Moderna.
Even at a 100% premium, Moderna would get facilities ready to go...
Add IDT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $45.13M | |||
| Open | High | Low | Value | Volume |
| 11.0¢ | 11.0¢ | 10.5¢ | $2.751K | 25.49K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 72418 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 19572 | 1 |
View Market Depth
| Last trade - 15.42pm 15/11/2024 (20 minute delay) ? |
| IDT (ASX) Chart |